FTX-6274
/ Fulcrum Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 24, 2025
FTX-6274, an EED inhibitor, demonstrates robust efficacy in castration resistant prostate cancer (CRPC)
(ESMO 2025)
- "In vivo mouse xenograft studies in AR positive prostate cancer models revealed that FTX-6274 demonstrated significant tumor growth inhibition compared to the EZH2 inhibitor mevrometostat. Further, our results indicate that FTX-6274 may have the potential to enhance efficacy as a combination therapy with ARPI in CRPC. Legal entity responsible for the study Fulcrum Therapeutics, Inc."
Clinical • Castration-Resistant Prostate Cancer • Diffuse Large B Cell Lymphoma • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
October 13, 2025
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
(StockTitan.net)
- "Preclinical data of FTX-6274 suggests potential for the treatment of castration resistant prostate cancer"
Preclinical • Castration-Resistant Prostate Cancer
1 to 2
Of
2
Go to page
1